Activin and Inhibin

CCR6 inhibitor 1 is a potent and selective CCR6 inhibitor, with IC 50 s of 0.45 and 6 nM for monkey and human CCR6 , much more selective at CCR6 over human CCR1 (IC 50 , &gt: 30000 nM), and CCR7 (IC 50 , 9400 nM). CCR6 inhibitor 1 markedly blocks

CCR6 inhibitor 1 is a potent and selective CCR6 inhibitor, with IC 50 s of 0.45 and 6 nM for monkey and human CCR6 , much more selective at CCR6 over human CCR1 (IC 50 , &gt: 30000 nM), and CCR7 (IC 50 , 9400 nM). CCR6 inhibitor 1 markedly blocks

CCR6 inhibitor 1 is a potent and selective CCR6 inhibitor, with IC 50 s of 0.45 and 6 nM for monkey and human CCR6 , much more selective at CCR6 over human CCR1 (IC 50 , &gt: 30000 nM), and CCR7 (IC 50 , 9400 nM). CCR6 inhibitor 1 markedly blocks

CCR6 inhibitor 1 is a potent and selective CCR6 inhibitor, with IC 50 s of 0.45 and 6 nM for monkey and human CCR6 , much more selective at CCR6 over human CCR1 (IC 50 , &gt: 30000 nM), and CCR7 (IC 50 , 9400 nM). CCR6 inhibitor 1 markedly blocks

CCR6 inhibitor 1 is a potent and selective CCR6 inhibitor, with IC 50 s of 0.45 and 6 nM for monkey and human CCR6 , much more selective at CCR6 over human CCR1 (IC 50 , &gt: 30000 nM), and CCR7 (IC 50 , 9400 nM). CCR6 inhibitor 1 markedly blocks

CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC 50 of 2.3 nM.In VitroCCT-251921 has acceptable aqueous solubility and demonstrates minimal activity when tested in a panel of 55 receptors, ion channels, and

CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC 50 of 2.3 nM.In VitroCCT-251921 has acceptable aqueous solubility and demonstrates minimal activity when tested in a panel of 55 receptors, ion channels, and

CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC 50 of 2.3 nM.In VitroCCT-251921 has acceptable aqueous solubility and demonstrates minimal activity when tested in a panel of 55 receptors, ion channels, and

CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC 50 of 2.3 nM.In VitroCCT-251921 has acceptable aqueous solubility and demonstrates minimal activity when tested in a panel of 55 receptors, ion channels, and

CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC 50 of 2.3 nM.In VitroCCT-251921 has acceptable aqueous solubility and demonstrates minimal activity when tested in a panel of 55 receptors, ion channels, and

CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC 50 of 2.3 nM.In VitroCCT-251921 has acceptable aqueous solubility and demonstrates minimal activity when tested in a panel of 55 receptors, ion channels, and

CCT129957 is an indole derivative and a potent phospholipase C-γ (PLC-γ) inhibitor with an IC 50 of ~3 μM and a GC 50 of 15 μM. CCT129957 inhibits Ca 2+ release in squamous carcinoma cells at ~15 μMIn VitroThe phenyl group on the left side sat in a